Alzheimer’s brain destructive plaques have been cleared in mice tests
US scientists have discovered how to rapidly clear the destructive plaques found in the brains of Alzheimer’s patients while they were testing a cancer drug on mice.
The study, published in the journal Science, reported the plaques were broken down at “unprecedented” speed.
Tests also showed an improvement in some brain function.
Researchers said the results were promising, but warned that successful drugs in mice often failed to work in people.
The exact cause of Alzheimer’s remains unknown, but one of the leading theories involves the formation of clumps of a protein called beta-amyloid. These damage and kill brain cells, eventually resulting in memory problems and the inability to think clearly.
Clearing protein plaques is a major focus of Alzheimer’s research and drugs are already being tested in human clinical trials.
In the body, the role of removing beta-amyloid falls to apolipoprotein E – or ApoE. However, people have different versions of the protein. Having the ApoE4 genetic variant is one of the biggest risk factors for developing the disease.
Alzheimer’s plaques (in brown) form around brain cells (in blue) and shrink parts of the brain
Scientists at the Case Western Reserve University in Ohio were investigating ways of boosting levels of ApoE, which in theory should reduce levels of beta-amyloid.
They tested bexarotene, which has been approved for use to treat cancers in the skin, on mice with an illness similar to Alzheimer’s.
After one dose in young mice, the levels of beta-amyloid in the brain were “rapidly lowered” within six hours and a 25% reduction was sustained for 70 hours.
In older mice with established amyloid plaques, seven days of treatment halved the number of plaques in the brain.
The study said there were improvements in brain function after treatment, in nest building, maze performance and remembering electrical shocks.
Researcher Paige Cramer said: “This is an unprecedented finding. Previously, the best existing treatment for Alzheimer’s disease in mice required several months to reduce plaque in the brain.”
The research is at a very early stage, and drugs often do not make the leap from animal experiment to human treatment.
Fellow researcher Prof. Gary Landreth said the study was “particularly exciting and rewarding” and held the “potential promise of a therapy for Alzheimer’s disease”.
However, he stressed that the drug had been tested in only three “mouse models” which simulate the early stages of the disease and are not Alzheimer’s.
Prof. Gary Landreth warned people not to “try this at home”, as the drug had not been proven to work in Alzheimer’s patients and there was no indication of what any dose should be.
“We need to be clear, the drug works quite well in mouse models of the disease. Our next objective is to ascertain if it acts similarly in humans,” he said.
Prof. Gary Landreth’s group is preparing to start trials in a small group of people to see if there is a similar effect in humans.
Alzheimer’s disease is likely to become more common as people live longer.